PepGen(PEPG) - 2024 Q4 - Annual Results

Exhibit 99.1 PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights – The Company today reported positive initial results from the ongoing FREEDOM-DM1 trial in patients with DM1; mean splicing correction of 12.3% and 29.1% in 5 and 10 mg/kg cohorts, respectively – – FREEDOM-DM1 15 mg/kg cohort is dosing, with results expected in second half of 2025 – – CONNECT1-EDO51 10 mg/kg cohort is fully enrolled, with results expected in third quarter of 2025 – BOSTON— Februar ...